CURRICULUM VITAE
Clark W. Johnson, MD
POSITION TITLE:
Medical Director
OFFICE ADDRESS:
Clinical Methods LLC
676 E. Vine St. #5
Murray, Utah, United States
CONTACT INFORMATION:
PROFESSIONAL LICENSURE:
Telephone: 801-290-5320
Fax: 801-290-5321
e-Mail: clark@clinicalmethods.com
Utah, State Medical License- MD
SPECIALIZATION:
Psychiatry
EDUCATION/TRAINING:
DEGREE
INSTITUTION AND LOCATION
(if applicable)
YEAR(s)
FIELD OF STUDY
St Luke’s – Roosevelt Hospital Center,
New York NY
Residency
2005-2009 Psychiatry Residency
University of Utah School of Medicine
Salt Lake City, UT
M.D.
2001-2005 Medicine
University of Utah
Salt Lake City, UT
Bachelor of
Arts
1994-2001 Spanish Literature
POSITIONS AND EMPLOYMENT:
2009-2011
2009-2010
2009-2010
2005-2009
Staff Psychiatrist, Southwest Washington Medical Center, Dept of Behavioral Health,
Vancouver WA
Staff Psychiatrist, LifeWorks Northwest, Adult Outpatient Program,
Portland OR
Primary Psychiatrist, Cascadia Behavioral Healthcare
Wilsonville OR
Psychiatry Resident, St Luke’s-Roosevelt Hospital Center
New York NY
OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:
2010
A Diplomat of the American Board of Psychiatry and Neurology
2011-Present Member of the Utah Psychiatric Association
Updated 7 November 2011
Initials _________________
Page 1 of 3
HONORS:
2011-Present
2008-2009
2004
2002
Instructor; Social Work Dept at Intermountain Health Care
Chief Resident; Saint Lukes-Roosevelt Hospital, NY NY
Scholarship to study Infectious Disease & Mental illess; Eldoret, Kenya
Scholarship to study Cross-Border Health Issues at University of Arizone in Tucson &
Nogales, Mexico
RESEARCH EXPERIENCE:
Year
2011
Indication
Adolescent
Schizophrenia
Role
Sub-I
2011
Adolescent
Schizophrenia
Sub-I
2011
Treatment
Resistant Major
Depression.
Sub-I
2011
Treatment
Resistant Major
Depression.
Sub-I
2011
Treatment
Resistant Major
Depression.
Sub-I
2011
Pediatric Bipolar I
Disorder
Sub-I
2011
Pediatric Bipolar I
Disorder
Sub-I
2011
Bipolar I Disorder
Sub-I
2008-2009
Prescription Opiate
Abuse
Rater &
Consultant
Updated 7 November 2011
Research Project
A 26 week, multi-center, open-label, flexible dose,
long-term safety trial of asenapine in adolescent
subjects with schizophrenia
An 8-week, placebo-controlled, double-blind,
randomized, fixed-dose efficacy and safety trial of
asenapine in adolescent subjects with schizophrenia
A Randomized, Double-Blind, Parallel Group,
Active- and Placebo-Controlled Study to Assess the
Efficacy and Safety of JNJ26489112 in Adult
Subjects With Treatment-Resistent Major Depressive
Disorder. Phase II
A Multicenter, Randomized, Double-blind, ActiveControlled, Comparative, Fixed-Dose, Dose
Response Study of the Efficacy and Safety of BMS820836 in Patients with Treatment Resistant Major
Depression.
A Double-Blind, 58 week Rollover Study to assess
the Safety and Tolerability of BMS-820836 in
Patients with Treatment Resistant Major Depression
Efficacy and Safety of 3-Week Fixed-Dose
Asenapine Treatment in Pediatric Acute Manic or
Mixed Episodes Associated with Bipolar I Disorder
A 26-Week Open Label, Flexible-Dose Trial of
Asenapine Extension Treatment to P06107 in
Pediatric Acute Manic or Mixed Episodes Associated
With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group,
Fixed-Dosage Study to Evaluate the Efficacy and
Safety of Armodafinil Treatment (150 and 200
mg/day) as Associated With Bipolar I Disorder
Prospective trial of clinical outcomes of
Buprenorphine detoxification in prescription opiate
abuse
Initials _________________
Page 2 of 3
2006-2009
Schizophrenia
Sub-I /
Rater
2008-2009
Metabolic
Syndrome
Sub-I /
Rater
2000
Acute Pain
Sub-I /
Rater
Collect data from patients with new onset
schizophrenia with marijuana use to better
understand the possibility of causation of
schizophrenia
A prospective study following hospitalized
psychiatric patients started on antipsychotics as their
metabolic profiles change over time once discharged
Evaluate patient response to various pain
management protocols in an emergency room setting.
__________________________________________________________
Signature
Updated 7 November 2011
Initials _________________
_____________________
Date
Page 3 of 3